RECRUITING

I Can Move with Purpose Now! a Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods. The name of the intervention used in this research study is: Cardiac Lifestyle Program (a 12-week, tailored nutrition and physical activity program)

Official Title

I Can Move with Purpose Now! a Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Quick Facts

Study Start:2024-03-01
Study Completion:2025-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05842603

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes.
  2. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  3. * Must have at least one cardiovascular risk factor including: Body mass index (BMI) \>25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study.
  1. * ECOG performance status \>2.
  2. * Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.

Contacts and Locations

Study Contact

Gabriela Hobbs, MD
CONTACT
617-724-1124
ghobbs@partners.org
Gabriella Hobbs, MD
CONTACT
617-724-1124
ghobbs@partners.org

Principal Investigator

Gabriela Hobbs, MD
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

Brigham and Women's Hospital
Boston, Massachusetts, 02215
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Gabriela Hobbs, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-01
Study Completion Date2025-01-01

Study Record Updates

Study Start Date2024-03-01
Study Completion Date2025-01-01

Terms related to this study

Keywords Provided by Researchers

  • Myeloproliferative Disorders
  • Leukemia

Additional Relevant MeSH Terms

  • Myeloproliferative Disorders
  • Leukemia